v3.24.4
Stock-based Compensation (FY) (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Schedule of Options Activity
The following table sets forth the summary of options activity, under the 2018 Plan and the 2021 Plans, for the nine months ended September 30, 2024:

 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands, except share-based data)
 
 
Total
Options
 
 
Weighted-Average
Exercise Price Per
Share
 
 
Weighted-Average
Remaining Contractual
Term (In Years)
 
 
Aggregate
Intrinsic
Value
Outstanding as of December 31, 2023
 
 
23,912
 
 
$68.39
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands, except share-based data)
 
 
Total
Options
 
 
Weighted-Average
Exercise Price Per
Share
 
 
Weighted-Average
Remaining Contractual
Term (In Years)
 
 
Aggregate
Intrinsic
Value
Forfeitures
 
 
(4,502)
 
 
11.96
 
 
 
 
 
 
Outstanding as of September 30, 2024
 
 
19,410
 
 
$81.48
 
 
6.6
 
 
$—
Exercisable as of September 30, 2024
 
 
17,478
 
 
$76.44
 
 
6.5
 
 
$—
Vested and expected to vest as of September 30, 2024
 
 
19,410
 
 
$81.48
 
 
6.6
 
 
$—
 
 
 
 
 
 
 
 
 
 
 
 
 
The following table sets forth the summary of options activity, under the 2018 Plan and the 2021 Plans, for the year ended December 31, 2023:

 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands, except share-based data)
 
 
Total
Options
 
 
Weighted-Average
Exercise Price
Per Share
 
 
Weighted-Average
Remaining Contractual
Term (In Years)
 
 
Aggregate
Intrinsic
Value
Outstanding as of December 31, 2022
 
 
51,166
 
 
$60.69
 
 
 
 
 
 
Vested exercised
 
 
(10,081)
 
 
$12.95
 
 
 
 
 
 
Forfeitures
 
 
(17,173)
 
 
$77.95
 
 
 
 
 
 
Outstanding as of December 31, 2023
 
 
23,912
 
 
$68.39
 
 
7.1
 
 
$—
Exercisable as of December 31, 2023
 
 
18,705
 
 
$54.36
 
 
6.8
 
 
$—
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands, except share-based data)
 
 
Total
Options
 
 
Weighted-Average
Exercise Price
Per Share
 
 
Weighted-Average
Remaining Contractual
Term (In Years)
 
 
Aggregate
Intrinsic
Value
Vested and expected to vest as of December 31, 2023
 
 
23,912
 
 
$68.39
 
 
7.1
 
 
$—
 
 
 
 
 
 
 
 
 
 
 
 
 
Schedule of Restricted Stock Unit and Restricted Stock Award Activity
The following table sets forth the summary of RSU and RSA activity, under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan, for the nine months ended September 30, 2024. RSAs were an immaterial portion of activity for the period:

 
 
 
 
 
 
 
 
 
 
Shares
 
 
Weighted Average Grant Date
Fair Value (i.e. Share Price)
Outstanding as of December 31, 2023
 
 
219,720
 
 
$86.78
Vested
 
 
(36,570)
 
 
67.15
Forfeited
 
 
(73,718)
 
 
47.72
Outstanding as of September 30, 2024
 
 
109,432
 
 
$119.66
 
 
 
 
 
 
 
The following table sets forth the summary of RSU and RSA activity, under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan, for the year ended December 31, 2023. RSAs were an immaterial portion of activity for the period:

 
 
 
 
 
 
 
 
 
 
Shares
 
 
Weighted Average Grant Date
Fair Value (i.e. Share Price)
Outstanding as of December 31, 2022
 
 
155,573
 
 
$199.74
Granted
 
 
212,089
 
 
27.26
Vested
 
 
(42,701)
 
 
202.28
Forfeited
 
 
(105,241)
 
 
86.95
Outstanding as of December 31, 2023
 
 
219,720
 
 
$86.78
 
 
 
 
 
 
 
Schedule of Stock-Based Compensation Expense
The following table sets forth the stock-based compensation under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan by expense type:

 
 
 
 
 
 
 
 
 
 
Three Months Ended
September 30,
 
 
Nine Months Ended
September 30,
(in thousands)
 
 
2024
 
 
2023
 
 
2024
 
 
2023
Research and development expenses
 
 
$275
 
 
$472
 
 
$499
 
 
$1,629
Selling, general and administrative expenses
 
 
1,432
 
 
1,684
 
 
4,386
 
 
4,824
Total
 
 
$1,707
 
 
$2,156
 
 
$4,885
 
 
$6,453
 
 
 
 
 
 
 
 
 
 
 
 
 
The following table sets forth the stock-based compensation under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan by award type:

 
 
 
 
 
 
 
 
 
 
Three Months Ended
September 30,
 
 
Nine Months Ended
September 30,
(in thousands)
 
 
2024
 
 
2023
 
 
2024
 
 
2023
Options
 
 
$71
 
 
$81
 
 
$216
 
 
$269
RSUs & RSAs
 
 
1,636
 
 
2,068
 
 
4,669
 
 
6,167
ESPP
 
 
—
 
 
7
 
 
—
 
 
17
Total
 
 
$1,707
 
 
$2,156
 
 
$4,885
 
 
$6,453
 
 
 
 
 
 
 
 
 
 
 
 
 
The following table sets forth the stock-based compensation under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan by expense type:

 
 
 
 
 
 
 
Year Ended December 31,
(in thousands)
 
 
2023
 
 
2022
Research and development expenses
 
 
$2,131
 
 
$2,134
Selling, general and administrative expenses
 
 
6,349
 
 
9,446
Total
 
 
$8,480
 
 
$11,580
 
 
 
 
 
 
 
The following table sets forth the stock-based compensation under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan by award type:

 
 
 
 
 
 
 
Year Ended December 31,
(in thousands)
 
 
2023
 
 
2022
Options
 
 
$352
 
 
$538
RSUs & RSAs
 
 
8,115
 
 
10,995
ESPP
 
 
13
 
 
117
Performance Awards
 
 
—
 
 
(70)
Total
 
 
$8,480
 
 
$11,580